2 studies find no link between bisphosphonates, higher cancer risk

04/22/2009 | Forbes

Two U.S. studies found no evidence that bisphosphonates, a class of osteoporosis medicines, increase the risk of esophageal cancer. The results counter FDA data citing cases of esophageal tumors linked to the drugs. An FDA epidemiologist clarified that the agency's report is not conclusive and is intended to "advise against the use of these drugs in patients with Barrett's esophagus, and recommend definitive studies."

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care